ArticleVirology journal2011
Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.
Article in Virology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex.Antimicrobial agents and chemotherapy · 2026Article
- Interspecies Differences in Cytomegalovirus Inhibition by Cardiac Glycosides-A Unique Role of the Alpha3 Isoform of the NaViruses · 2025Article
- Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice.Microbiology spectrum · 2023Article
- Article
- Article
- T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.The Journal of clinical investigation · 2021Article
- Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus.Journal of medicinal chemistry · 2020Article
- Degradation of SAMHD1 Restriction Factor Through Cullin-Ring E3 Ligase Complexes During Human Cytomegalovirus Infection.Frontiers in cellular and infection microbiology · 2020Article
- Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.Antimicrobial agents and chemotherapy · 2019Article
- Genome-wide analysis of regulatory G-quadruplexes affecting gene expression in human cytomegalovirus.PLoS pathogens · 2018Article
- Digitoxin Suppresses Human Cytomegalovirus Replication via NaJournal of virology · 2018Article
- Article
- Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus.PLoS pathogens · 2016Article
- Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2016Article
- Bacterial Muramyl Dipeptide (MDP) Restricts Human Cytomegalovirus Replication via an IFN-β-Dependent Pathway.Scientific reports · 2016Article
- Human Cytomegalovirus Inhibits the PARsylation Activity of Tankyrase--A Potential Strategy for Suppression of the Wnt Pathway.Viruses · 2015Article
- Broad-spectrum non-nucleoside inhibitors of human herpesviruses.Antiviral research · 2015Article
- Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.Antimicrobial agents and chemotherapy · 2015Article
- In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.